DEVOTE: A landmark safety outcomes trial for Tresiba® U-1001

DEVOTE is a safety outcomes trial comparing Tresiba® U-100 vs insulin glargine U-100 in adults with type 2 diabetes and ASCVD. See how Tresiba® U-100 performed, comparing risk of major adverse cardiovascular events and rates of severe hypoglycemia between the two products. Read Important Safety & Prescribing Info.

Source:DEVOTE: A landmark safety outcomes trial for Tresiba® U-1001